COMPANY OVERVIEW

MEBIAS, an emerging leader in the field of pathway-selective G-protein coupled receptor (GPCR) drug discovery. MEBIAS was founded to establish an alternative discovery model, offering a validated, rapid, and highly efficient drug discovery platform.

---

LOCATION

Philadelphia, PA, USA

---

THERAPEUTIC AREAS

Pain

---

WEBSITE

https://mebiasdiscovery.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Nov 29, 2022

Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder

Oct 29, 2020

Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder

Sep 24, 2018

MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate

Oct 16, 2017

MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC

For More Press Releases

---